Linsitinib (OSI-906)

Catalog No.S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 49 Publications

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk NWnFTlNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMEK4NFYh|ryP MXTTRW5ITVJ?
KS-1 NFXJS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnzTWM2OD1yLkCzPFM2KM7:TR?= MoPKV2FPT0WU
TE-11 MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIX4OFNKSzVyPUCuNFc5OjJizszN M2mx[nNCVkeHUh?=
EW-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vIe2lEPTB;MD6wPFU5PSEQvF2= NF\5XnRUSU6JRWK=
HMV-II NIDzXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXyWm5KSzVyPUCuNFg5PDZizszN M4PuU3NCVkeHUh?=
COLO-205 M17B[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMUC0OVQh|ryP NFP1SYFUSU6JRWK=
ES1 M2LHe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonTTWM2OD1yLkGwOlk3KM7:TR?= NYTBVm5wW0GQR1XS
GDM-1 M4PSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLNU5RYUUN3ME2wMlE{Pjd{IN88US=> MXXTRW5ITVJ?
ML-2 NH7QV3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMUW4PVYh|ryP MUjTRW5ITVJ?
Saos-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PnUmlEPTB;MD6xOlUzPiEQvF2= MWfTRW5ITVJ?
NCI-H1355 M1G0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XzWmlEPTB;MD6xPFE{PSEQvF2= Mmr1V2FPT0WU
G-401 M{DvOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3XPFB5UUN3ME2wMlE5OjNizszN MXrTRW5ITVJ?
EW-16 M{H5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHhNoVKSzVyPUCuNVg4PzdizszN NGO2NpdUSU6JRWK=
EW-7 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwMUi4PFEh|ryP NEOxXmNUSU6JRWK=
NCI-H727 MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXXTWM2OD1yLkG5O|k1KM7:TR?= MVfTRW5ITVJ?
LCLC-97TM1 NWHuPZc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHm5NGZKSzVyPUCuNlA6PTVizszN NYfs[IVpW0GQR1XS
NCI-H650 NUGyR5p4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHuxSIVKSzVyPUCuNlE{QDRizszN NHf2XZZUSU6JRWK=
NCI-H2122 NEjTdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly4TWM2OD1yLkKzNlk6KM7:TR?= NYjobFNDW0GQR1XS
SK-N-DZ NVHreVZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1W2WmlEPTB;MD6yN|Y6QCEQvF2= NE\wc|hUSU6JRWK=
HT-29 NEi4PINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwMkSyOFgh|ryP M4fESXNCVkeHUh?=
LB771-HNC MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMkW5NVUh|ryP MYTTRW5ITVJ?
HT-144 NIqybZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMk[xPVEh|ryP Mn7GV2FPT0WU
LAN-6 NYi3c5pDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwMk[zOFgh|ryP NWXZeXE6W0GQR1XS
EW-18 NVrtdpRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknOTWM2OD1yLkK3NFAyKM7:TR?= MUXTRW5ITVJ?
LS-1034 M3L6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwMkexN|Ih|ryP NWjsN4t1W0GQR1XS
EW-11 MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHlUo9KSzVyPUCuNlg1OzJizszN M1nYXHNCVkeHUh?=
SNU-C1 NV:yZnJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwMkmzNVMh|ryP NFm4O|RUSU6JRWK=
RS4-11 MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLPe2J2UUN3ME2wMlM{PzV6IN88US=> NEG5NJRUSU6JRWK=
ES4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwNEGwN|gh|ryP M4WyTnNCVkeHUh?=
COLO-320-HSR NILmT5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwNEGzOlgh|ryP M33TOnNCVkeHUh?=
NB10 NInPNYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwNEW0N|ch|ryP NHS3fJNUSU6JRWK=
BFTC-905 M{jGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3YTWM2OD1yLkS2O|U5KM7:TR?= MnrlV2FPT0WU
A375 M3rMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLXXpJKSzVyPUCuOFc3OTdizszN NWH2ZWF6W0GQR1XS
SJRH30 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fDVWlEPTB;MD61NFgzOiEQvF2= NHPD[XdUSU6JRWK=
NOS-1 MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwNUKyOlch|ryP MXvTRW5ITVJ?
SIG-M5 NVz4NlltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HZTWlEPTB;MD61N|U2PyEQvF2= MUTTRW5ITVJ?
DOK M2f2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmG4TWM2OD1yLkW1OkDPxE1? MWfTRW5ITVJ?
NB69 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf0eYhKSzVyPUCuOVgzPTdizszN MlPjV2FPT0WU
SK-NEP-1 MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3GdXo6UUN3ME2wMlYxOjN4IN88US=> MXLTRW5ITVJ?
SK-MM-2 NEXtT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1q4TGlEPTB;MD62OVQ6OSEQvF2= NIXTfW9USU6JRWK=
NCI-H358 NGXYVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjyW2FZUUN3ME2wMlY4ODh{IN88US=> NHzodVZUSU6JRWK=
RH-1 Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwN{S4OVkh|ryP MYfTRW5ITVJ?
NH-12 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7ZTWM2OD1yLke2NFQ3KM7:TR?= NH;aPWRUSU6JRWK=
TE-12 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LYUmlEPTB;MD63OlQ5PiEQvF2= NF\P[5ZUSU6JRWK=
COLO-668 NH3ROohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnl[3hKSzVyPUCuPFQ3PjZizszN NX[4S25pW0GQR1XS
PANC-08-13 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITCPYZKSzVyPUCuPFY{PzdizszN MX3TRW5ITVJ?
HCC2998 NWL3d4xqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;mTWM2OD1yLki4NlY{KM7:TR?= M1zlWXNCVkeHUh?=
ABC-1 NH7wdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jydWlEPTB;MD65NFM2OiEQvF2= MlH5V2FPT0WU
ES6 MorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXiVlhKSzVyPUCuPVExPjZizszN MmnCV2FPT0WU
SNU-387 MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwOUmzPVMh|ryP Ml:wV2FPT0WU
CMK NEXBXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nOVWlEPTB;MD65PVkzQSEQvF2= NXXNTpZLW0GQR1XS
SJSA-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\vNlRKSzVyPUGuNFM3PTNizszN MnnzV2FPT0WU
SIMA NV3zZpBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFwME[4NlUh|ryP NGXzeFdUSU6JRWK=
ES3 NGnxeppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTFwMUKyPVch|ryP M4S3fnNCVkeHUh?=
IGROV-1 Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\DTWlEPTB;MT6xOVQ1PCEQvF2= MojtV2FPT0WU
MEL-JUSO M1;ZUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnpR5lKSzVyPUGuNVU4PTlizszN NHfucW5USU6JRWK=
T84 MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULVSJRjUUN3ME2xMlIxQTF2IN88US=> NYXub4RiW0GQR1XS
CAL-85-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjOTWM2OD1zLkKzNVM5KM7:TR?= NFWzcWxUSU6JRWK=
RD MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmO5TWM2OD1zLkK2OFU2KM7:TR?= MXjTRW5ITVJ?
TE-8 NXjJPFdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYruWHpLUUN3ME2xMlMyPDZ{IN88US=> NH;0RlRUSU6JRWK=
L-363 MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;DOW1KSzVyPUGuN|QzODhizszN Ml75V2FPT0WU
EKVX MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTFwM{S1Olgh|ryP MoXBV2FPT0WU
SK-MEL-3 M{CzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTFwNEi1OVYh|ryP NHvJPVZUSU6JRWK=
TGBC24TKB Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXZdmRKSzVyPUGuOVAyQTNizszN MWPTRW5ITVJ?
NCI-H1770 MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwNUGxNVMh|ryP M3;EdnNCVkeHUh?=
HuH-7 NHH4dJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPlTWM2OD1zLk[wNFk5KM7:TR?= NGPMVmdUSU6JRWK=
HL-60 NVvUVm1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml22TWM2OD1zLk[2PVI5KM7:TR?= MUfTRW5ITVJ?
TE-1 M3f5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zs[WlEPTB;MT63NFk1PSEQvF2= Ml\vV2FPT0WU
LC-2-ad M4jsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPlTWM2OD1zLkezPFg4KM7:TR?= NHXjdHpUSU6JRWK=
LB647-SCLC MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHToTJpKSzVyPUGuO|Y2QDNizszN M{i0VXNCVkeHUh?=
NCI-H2171 MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j3VmlEPTB;MT63O|cyPiEQvF2= MlPxV2FPT0WU
SK-PN-DW M2TXd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnjbGxKSzVyPUGuPVEzQThizszN MYfTRW5ITVJ?
MC-IXC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHlb5VKSzVyPUGuPVg6QCEQvF2= MUTTRW5ITVJ?
LS-513 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIGwV|RKSzVyPUKuNFU{ODVizszN NWnNUFI2W0GQR1XS
EW-3 NF:zb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M370W2lEPTB;Mj6wPVg1PCEQvF2= M4jxeHNCVkeHUh?=
OPM-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTJwMUCyJO69VQ>? MoW2V2FPT0WU
LP-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7SWm9KSzVyPUKuNlU5ODdizszN M3OyT3NCVkeHUh?=
LU-134-A M{DxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7qdpZKSzVyPUKuNlc4KM7:TR?= MWrTRW5ITVJ?
CP66-MEL MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLXTWM2OD1{LkK5NFE1KM7:TR?= NXjpZ4R{W0GQR1XS
HCC1143 MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvndHNKSzVyPUKuOFU{PjhizszN M{\KcHNCVkeHUh?=
LOXIMVI NWXSSYV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrCV2xKSzVyPUKuOlAzOSEQvF2= MUHTRW5ITVJ?
TE-10 MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y1RWlEPTB;Mj63NFg{QCEQvF2= NFL0UZRUSU6JRWK=
NCI-H1882 MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzQN|RHUUN3ME2yMlc2OjJ5IN88US=> NHX1RllUSU6JRWK=
CHP-126 Ml7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFf3XYpKSzVyPUKuO|Y{OTdizszN Mlz4V2FPT0WU
NCI-H1623 NWSwNGk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS1VnNKSzVyPUKuPVIxOjRizszN MWTTRW5ITVJ?
GB-1 M4jDPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn[xTWM2OD1{LkmzOFA1KM7:TR?= MX;TRW5ITVJ?
RCC10RGB M2fuV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTJwOUWyPFEh|ryP NG\i[mRUSU6JRWK=
NCI-H2141 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXroZXhFUUN3ME2yMlk3QDl4IN88US=> MoH5V2FPT0WU
GI-ME-N M{\vV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTNwMEC1OlUh|ryP MUHTRW5ITVJ?
NCI-H526 NV7FdIV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXhOIlKSzVyPUOuNFQxQDVizszN Mlu5V2FPT0WU
NCI-H747 M4\xPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17DWGlEPTB;Mz6wOFk6OiEQvF2= M4nPSnNCVkeHUh?=
SNU-423 M3XHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULnXVJxUUN3ME2zMlIxOzF|IN88US=> NE\Reo9USU6JRWK=
A427 MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTNwMkW2PVkh|ryP MmjxV2FPT0WU
CAL-12T NFnKS29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjGVpJKSzVyPUOuOFA4OTNizszN NWTiR3lmW0GQR1XS
LU-99A NFHCbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDxcpBKSzVyPUOuOFcyODVizszN MXXTRW5ITVJ?
MS-1 NILhV4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTRTWM2OD1|LkWzOFI6KM7:TR?= NELZemVUSU6JRWK=
SK-LU-1 MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK2eWxKSzVyPUOuO|YzQTVizszN MkjzV2FPT0WU
SW837 NY\WXpVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLRfnBKSzVyPUOuO|Y{OzNizszN NXjtZ41NW0GQR1XS
ES8 M4fWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfHbHlKSzVyPUOuPFM5PzdizszN NFjCPJpUSU6JRWK=
MZ2-MEL NWKwbIp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrpZmtWUUN3ME2zMlkzODh4IN88US=> M1q0PXNCVkeHUh?=
TGW NGm3W5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTRwMEGzNVEh|ryP NVfzZoU3W0GQR1XS
GP5d MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\YblhyUUN3ME20MlA2OzZ{IN88US=> NHi0VVdUSU6JRWK=
BB49-HNC M3rGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe1TWM2OD12LkG1NlE{KM7:TR?= M13D[HNCVkeHUh?=
NB13 NGTJcXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fEZmlEPTB;ND6yOlg5PyEQvF2= NFvHcWJUSU6JRWK=
NTERA-S-cl-D1 M4TyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NImySXhKSzVyPUSuNlg3OTVizszN M1vaZnNCVkeHUh?=
NCI-H1648 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTRwMkm4NVkh|ryP NG\hfIlUSU6JRWK=
LCLC-103H Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTRwM{KxPVUh|ryP Mm\tV2FPT0WU
LS-411N NEP5UWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTRwNES4PFUh|ryP NHmxdYtUSU6JRWK=
NCI-H1092 NFzpWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTRwNEW2PFch|ryP MmPpV2FPT0WU
PANC-10-05 NIPLbZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PkWWlEPTB;ND62PVg1KM7:TR?= NFe3[pZUSU6JRWK=
DK-MG Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDv[pBKSzVyPUSuPFA6OzNizszN NH\CdohUSU6JRWK=
OVCAR-5 M3vtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTRwOEGyNlYh|ryP MoT5V2FPT0WU
CAL-39 NVPyS4NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTRwOEe2O{DPxE1? M4DJZXNCVkeHUh?=
TE-441-T NV;mVVNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEflU2RKSzVyPUSuPVA2OzdizszN MVXTRW5ITVJ?
MOLT-16 M1T5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS4N4lKSzVyPUSuPVUzPTNizszN MVvTRW5ITVJ?
MCF7 NGLMN5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\uUJhKSzVyPUWuNVQ2OTdizszN MYTTRW5ITVJ?
CAPAN-1 M1PlRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37xWGlEPTB;NT6yOVcxPyEQvF2= M3zy[nNCVkeHUh?=
PSN1 NHH3dFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTVwMkeyN|Uh|ryP NUfCcmJzW0GQR1XS
NCI-H292 NGq0NXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTVwM{CwOFQh|ryP MmHUV2FPT0WU
CPC-N MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;iU2hYUUN3ME21MlM6PDF7IN88US=> NEPnXGZUSU6JRWK=
DoTc2-4510 NXv5NXkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTVwNEWzO|Eh|ryP M2P4bXNCVkeHUh?=
LB1047-RCC M{HVR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnSO3VKSzVyPUWuOVU6OzNizszN NGrkRohUSU6JRWK=
MHH-ES-1 NVTwUoZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTVwNUm5NFch|ryP MVjTRW5ITVJ?
NMC-G1 NU\MfWVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTGTWM2OD13LkewNlI4KM7:TR?= M4HDSXNCVkeHUh?=
SW1710 NImzcFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf0W|RNUUN3ME21Mlc1PzVzIN88US=> NXOxdWNSW0GQR1XS
YAPC M1LQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTVwN{[yNFEh|ryP M{m1e3NCVkeHUh?=
22RV1 M1\tSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTVwOECwNVkh|ryP MWTTRW5ITVJ?
COLO-679 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fhRmlEPTB;NT64PFk1QCEQvF2= M1fEd3NCVkeHUh?=
TCCSUP M3HtTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVztdZlTUUN3ME21Mlk{OjV7IN88US=> NV;CT286W0GQR1XS
C2BBe1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\md2lEPTB;NT65N|k4KM7:TR?= M{m2c3NCVkeHUh?=
TE-15 MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTZwME[2NFUh|ryP MnvGV2FPT0WU
SCLC-21H NICyUZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjlTWM2OD14LkGwPFQ{KM7:TR?= NVyzfWNlW0GQR1XS
EoL-1-cell M2HPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTZwMU[1OlMh|ryP MkmyV2FPT0WU
NKM-1 NHfYdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ztOGlEPTB;Nj6xOlcyKM7:TR?= M1PUTXNCVkeHUh?=
NCI-H1304 NVPjTGs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:5bmhKSzVyPU[uNlc1OjhizszN M{\NU3NCVkeHUh?=
NB6 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFW2WFNKSzVyPU[uNlk3OjJizszN Mn;LV2FPT0WU
NALM-6 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHz5cnJKSzVyPU[uN|MzOyEQvF2= MWPTRW5ITVJ?
NCI-H522 M1e3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfqW5ZKSzVyPU[uN|M{ODZizszN NFuwTJZUSU6JRWK=
MV-4-11 M2rR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoC5TWM2OD14LkO3NFc6KM7:TR?= MnPkV2FPT0WU
LB2241-RCC MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn30TWM2OD14LkO4OlY4KM7:TR?= MYDTRW5ITVJ?
NCI-H1417 NF:4emVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\GOGlEPTB;Nj60NFg1PyEQvF2= NEXiZo1USU6JRWK=
HT-1197 NETRc2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTuTWM2OD14LkW3NVIzKM7:TR?= M{PqT3NCVkeHUh?=
P30-OHK NFfCVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTZwNkK3O{DPxE1? M1jMdnNCVkeHUh?=
ALL-PO NGTUcXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DpO2lEPTB;Nj63NVkyPiEQvF2= NUC3O5FYW0GQR1XS
OVCAR-4 M2KxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTZwN{W0NFUh|ryP MXLTRW5ITVJ?
HCC2157 MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELFNVhKSzVyPU[uO|c1PzVizszN Mo[4V2FPT0WU
NCI-H838 NWC2[WY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTZwOU[0PUDPxE1? NEO3ZYxUSU6JRWK=
NCI-H1299 M4TTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTZwOUewPUDPxE1? NF\vNZRUSU6JRWK=
SW954 NUW3N5VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn3TWM2OD15LkKwNFY5KM7:TR?= M2DRdHNCVkeHUh?=
NCI-H441 NYfYNmE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDNbHVKSzVyPUeuN|QxPjVizszN MWDTRW5ITVJ?
SK-MEL-2 MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkftTWM2OD15LkS4N|c{KM7:TR?= MVLTRW5ITVJ?
KARPAS-45 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnu5TWM2OD15Lk[1PVI6KM7:TR?= Mli3V2FPT0WU
CAL-54 NXLyZ2lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLkdWdKSzVyPUeuPFI6PzdizszN MWXTRW5ITVJ?
KYSE-180 MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HhPWlEPTB;Nz64PFk1OSEQvF2= M1PmRXNCVkeHUh?=
NCI-H187 NHO1TopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rPPGlEPTB;Nz65OVk1PyEQvF2= NXPxdlB1W0GQR1XS
RT-112 NFnuNohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlGyTWM2OD16LkC5Olc4KM7:TR?= NW\6fVBKW0GQR1XS
NCI-H1437 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX70WYw4UUN3ME24MlA6Pzl3IN88US=> NW\IZ5REW0GQR1XS
SNU-449 MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7OW4N{UUN3ME24MlI5Ojd{IN88US=> NVi4NI5UW0GQR1XS
HCC1187 MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRThwMkmzPVEh|ryP NYnvbZlSW0GQR1XS
NCI-H2030 M1rzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLPTWM2OD16LkO3O|E1KM7:TR?= MnXUV2FPT0WU
HuO-3N1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PVR2lEPTB;OD6zO|g1PCEQvF2= Ml7uV2FPT0WU
COLO-792 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHSb|BKSzVyPUiuOFE2OjdizszN MkfoV2FPT0WU
MIA-PaCa-2 NVLSW5lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTWS|dKSzVyPUiuPFU2ODhizszN MVPTRW5ITVJ?
SK-N-FI MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:4TWM2OD17LkC0NlUh|ryP MnLtV2FPT0WU
MMAC-SF M4HTdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGq3XpFKSzVyPUmuNFk4PTFizszN M3PM[3NCVkeHUh?=
NCI-H28 NGfkb5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrGTWM2OD17LkGwOFY6KM7:TR?= MYfTRW5ITVJ?
ETK-1 NIn1XZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K3PGlEPTB;OT6yPVk4PCEQvF2= M4Hl[XNCVkeHUh?=
NCI-H1993 NXzm[nNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrHVlJKSzVyPUmuOFQzPjFizszN NHywTXlUSU6JRWK=
no-11 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH3TWM2OD17LkS3NVIh|ryP M3HYU3NCVkeHUh?=
ChaGo-K-1 NHzLbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjDfFVlUUN3ME25MlUyPTh|IN88US=> NYjOZlB3W0GQR1XS
NCCIT MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL6c41nUUN3ME25MlU{OTZ7IN88US=> NWrmXppVW0GQR1XS
SAS M4TobWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnztTWM2OD1zMD6yOFgh|ryP MW\TRW5ITVJ?
A673 NV6zUo4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHhXmI4UUN3ME2xNE4{PzB2IN88US=> NX\SS3p[W0GQR1XS
NCI-H1522 NXjnb5dnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTFyLkO3NFch|ryP M{DiOnNCVkeHUh?=
NCI-H810 MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFyLkO5NFch|ryP NI\0dZNUSU6JRWK=
IST-MES1 NV\FR2JyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDBdVBCUUN3ME2xNE41PTZ2IN88US=> NIDrVYlUSU6JRWK=
GR-ST NXnucnl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HPfWlEPTB;MUCuOVAzPCEQvF2= MXPTRW5ITVJ?
SUP-T1 MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTFyLkezNVch|ryP NFXFTY1USU6JRWK=
NB5 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTFyLkmwNlIh|ryP NFLIdYZUSU6JRWK=
MZ1-PC M2fxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTFyLkm1O|Eh|ryP MX;TRW5ITVJ?
SK-CO-1 M2\kZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGKyZoRKSzVyPUGwMlk6OzFizszN NGjCR2FUSU6JRWK=
Capan-2 M3W2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzn[JJNUUN3ME2xNU4{OTl6IN88US=> M3\WSXNCVkeHUh?=
697 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\2TWM2OD1zMT62O|U4KM7:TR?= M12wW3NCVkeHUh?=
REH NF3sUYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF6wPGVKSzVyPUGxMlc1PTFizszN NEfXVpVUSU6JRWK=
GI-1 Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfWPJFKSzVyPUGxMlg3OTVizszN MWTTRW5ITVJ?
BB65-RCC NWPIOYk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTF{LkC5NVYh|ryP M4[5cnNCVkeHUh?=
NCI-H1651 M4rrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIW1fI5KSzVyPUGyMlI1PzhizszN NHvRdINUSU6JRWK=
NCI-H1618 NYHYfHVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH2UnNKSzVyPUGyMlM6PzZizszN MYDTRW5ITVJ?
NCI-H2081 NVH0Wll{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W3fGlEPTB;MUKuOlE1OSEQvF2= M3\Wd3NCVkeHUh?=
GCIY MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnftTWM2OD1zMj63NlE{KM7:TR?= MnfjV2FPT0WU
NY NFPqU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7Wc3B2UUN3ME2xN{4xPjR|IN88US=> NVH3TWVOW0GQR1XS
PANC-03-27 MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;Cd3pKSzVyPUGzMlA5ODdizszN M4DFTHNCVkeHUh?=
BHY Ml;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF|LkKxNlEh|ryP MYrTRW5ITVJ?
SK-OV-3 MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTF|LkO3OlMh|ryP Mo\2V2FPT0WU
5637 M2DCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfkTWM2OD1zMz63O|U6KM7:TR?= MUPTRW5ITVJ?
LC-1F NV\RbW9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkS0TWM2OD1zND6wN|U3KM7:TR?= MV3TRW5ITVJ?
SNB75 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\4TWM2OD1zND6wN|g{KM7:TR?= Mo\iV2FPT0WU
CHP-212 NFPnOWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF2LkC0OlQh|ryP MXPTRW5ITVJ?
HT-1376 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nyZmlEPTB;MUSuNVEzPiEQvF2= NHj3NJlUSU6JRWK=
MONO-MAC-6 NIXDVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPHTWM2OD1zND6xOVAzKM7:TR?= M3;pTXNCVkeHUh?=
CA46 M3zJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTF2LkG4Nlch|ryP NGjM[mJUSU6JRWK=
SCC-15 Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvWTWM2OD1zND61OVg{KM7:TR?= MUfTRW5ITVJ?
ATN-1 NF;qbJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjTeWN4UUN3ME2xOE43PjJ5IN88US=> NEfqR4NUSU6JRWK=
NCI-H2405 NHKxd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmG5TWM2OD1zND64NVU4KM7:TR?= M3n4cHNCVkeHUh?=
NCI-H716 NFe5XYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[2dWpKSzVyPUG0Mlg1QTNizszN NID1PHdUSU6JRWK=
SW620 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PCW2lEPTB;MUSuPVAyPCEQvF2= MU\TRW5ITVJ?
NCI-H226 NEKycolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTF2LkmwPFUh|ryP NX\U[XRtW0GQR1XS
SW962 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{CzcWlEPTB;MUSuPVQ{OiEQvF2= MkC5V2FPT0WU
KYSE-150 NUjE[GlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTF2Lkm1OUDPxE1? MVjTRW5ITVJ?
OCUB-M MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3wTWM2OD1zND65PFg{KM7:TR?= NWTKbIdlW0GQR1XS
ES7 Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoOxTWM2OD1zNT6wPVg1KM7:TR?= NUjRR|VuW0GQR1XS
SW1463 M{jmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVux[ZFuUUN3ME2xOU41OjJ|IN88US=> MVPTRW5ITVJ?
CAKI-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF3LkWzOFYh|ryP NGfJV21USU6JRWK=
MKN28 NH\6OnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrRXJhMUUN3ME2xOU42PDd7IN88US=> MVPTRW5ITVJ?
SW13 NFjvb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTF3Lk[xPEDPxE1? M3zmeXNCVkeHUh?=
A3-KAW MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfuS3lKSzVyPUG1Mlk3QTdizszN MVHTRW5ITVJ?
LU-65 NH3mcYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X0SWlEPTB;MUWuPVc3QCEQvF2= NFyyTI1USU6JRWK=
Calu-1 NUTlcWd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[yTWM2OD1zNj6wN|Y5KM7:TR?= M1;XUHNCVkeHUh?=
ST486 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fncmlEPTB;MU[uNFQ{OSEQvF2= NW\I[4djW0GQR1XS
BB30-HNC NIXJUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELSXoFKSzVyPUG2MlEzPDZizszN MoKzV2FPT0WU
EGI-1 NWjQbXlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHuTWM2OD1zNj60OFYh|ryP MWPTRW5ITVJ?
SH-4 M{nqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFO3OI9KSzVyPUG2MlQ4OzFizszN MX7TRW5ITVJ?
MN-60 NUnFT|UxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LLSGlEPTB;MUeuNlI6PyEQvF2= NXPQNXJiW0GQR1XS
MPP-89 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnGNodKSzVyPUG3MlI1PTlizszN NGHCdpVUSU6JRWK=
A2780 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF5LkSxN|kh|ryP NHvYdFVUSU6JRWK=
Daoy NWTDdG0xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\abIRzUUN3ME2xO{41Pjl3IN88US=> MlLnV2FPT0WU
NCI-H2126 NWC5R5R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDtTWM2OD1zNz60O|cyKM7:TR?= NHzlbGZUSU6JRWK=
NCI-H1563 MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPlcYFKSzVyPUG3MlQ6OTdizszN NWTKOItrW0GQR1XS
8-MG-BA MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jY[GlEPTB;MUeuOlY1QCEQvF2= NHy5eVRUSU6JRWK=
786-0 M{XEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXxVpdKSzVyPUG3Mlg{PTNizszN NX7rRpkyW0GQR1XS
AM-38 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTqSlB5UUN3ME2xO{46OzB4IN88US=> NInFOFlUSU6JRWK=
COLO-824 NIDDUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDoO412UUN3ME2xPE41PDN4IN88US=> MlzhV2FPT0WU
SK-MEL-30 NYPUWlQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTF6LkWwPFIh|ryP MkjqV2FPT0WU
CESS NWj5U3FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTF6Lke2NFkh|ryP M4fxOXNCVkeHUh?=
BL-70 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF6LkixOVYh|ryP MWDTRW5ITVJ?
NCI-H2170 NWTzVnJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTF6LkmxO|kh|ryP NGHIOGRUSU6JRWK=
HT-3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjtR4Z2UUN3ME2xPE46QDNizszN NFTCb29USU6JRWK=
BOKU NVrp[5ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfpTWM2OD1zOT6wN|gyKM7:TR?= Mlu4V2FPT0WU
HPAF-II MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfWcGNKSzVyPUG5MlMxOTVizszN Ml\jV2FPT0WU
KGN NUPpSHE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUi0foo2UUN3ME2xPU41PzZ3IN88US=> M1r5PHNCVkeHUh?=
MC-CAR NX3Bd2JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfEcHZKSzVyPUG5MlY{OTNizszN MmjDV2FPT0WU
BHT-101 M1fLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTF7Lke3O{DPxE1? M1[0W3NCVkeHUh?=
SW1783 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF7Lke4NFYh|ryP NWHSfmJsW0GQR1XS
KP-N-YN M{LsU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPPTWM2OD1{MD6wNlYzKM7:TR?= MV7TRW5ITVJ?
LU-165 NVTEWZdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\PTWM2OD1{MD61OVcyKM7:TR?= NUXJeodTW0GQR1XS
GOTO M2jlUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G4UGlEPTB;MkCuOlQ2OSEQvF2= NYDJVFg1W0GQR1XS
EFM-19 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33DcWlEPTB;MkGuNFcyPiEQvF2= NW\lSY5UW0GQR1XS
CTV-1 NGPpWo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfsSXE5UUN3ME2yNU4yODV2IN88US=> NUHMc2pIW0GQR1XS
HEL M{DvR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJzLkSyNVYh|ryP MnW4V2FPT0WU
SNU-C2B M{\jOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTlTWM2OD1{MT60NlYh|ryP MkHrV2FPT0WU
ECC4 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jncmlEPTB;MkGuO|A4KM7:TR?= NXXxRZFXW0GQR1XS
NEC8 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1X5VWlEPTB;MkGuPFM3QCEQvF2= NWDNUmpDW0GQR1XS
KMOE-2 NXrPWG8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\GTWM2OD1{MT64PVIyKM7:TR?= MkjwV2FPT0WU
NCI-H524 NYjEdm42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnq1TWM2OD1{Mj6wPFA5KM7:TR?= NGHocnRUSU6JRWK=
WSU-NHL NEHFXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XCTmlEPTB;MkKuNVU4PyEQvF2= MVzTRW5ITVJ?
SF126 NYjBZ3NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlm1TWM2OD1{Mj6yOFY6KM7:TR?= NF7GW21USU6JRWK=
HOP-92 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJ{LkOxOlch|ryP NIGzU|VUSU6JRWK=
CTB-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrEbpdKSzVyPUKyMlQ3PzdizszN NVK2O5BWW0GQR1XS
KYSE-270 NF\OcotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTJ{LkmzOVch|ryP M3;Ub3NCVkeHUh?=
SK-MEL-24 M{fMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTJ|LkG4O{DPxE1? NXn1eYVRW0GQR1XS
Calu-3 Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfqVGI4UUN3ME2yN{4zOTJ6IN88US=> NIfGemNUSU6JRWK=
GAMG M3vhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrITWM2OD1{Mz6yN|Y4KM7:TR?= M{HBfXNCVkeHUh?=
SW1573 M1S4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHtVXRQUUN3ME2yN{44PDF3IN88US=> MlLKV2FPT0WU
MHH-NB-11 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PQcGlEPTB;MkSuNFE6PCEQvF2= M3zYZXNCVkeHUh?=
TK10 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3S2W2lEPTB;MkSuOVAyOyEQvF2= Ml7qV2FPT0WU
LB373-MEL-D MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHN[JpKSzVyPUK0MlYxPjRizszN M1rzUXNCVkeHUh?=
KALS-1 NGTzdFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L0OmlEPTB;MkSuO|MzPyEQvF2= MV\TRW5ITVJ?
HUTU-80 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PQS2lEPTB;MkWuPFA{OiEQvF2= MWDTRW5ITVJ?
HuP-T3 NFPSW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDD[GRKSzVyPUK2MlE3PzRizszN NFHhSHZUSU6JRWK=
OE19 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTJ4LkKxOVMh|ryP NITiNndUSU6JRWK=
J82 NWTBOHdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\UbmJKSzVyPUK2MlI1PzFizszN MYfTRW5ITVJ?
DU-4475 M3izVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJ4LkO4NVkh|ryP NIrqe|BUSU6JRWK=
DMS-53 Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLvTWM2OD1{Nj61NVM5KM7:TR?= NHm3c2xUSU6JRWK=
COLO-741 Ml7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;PNYVKSzVyPUK2Mlg{PDRizszN MX\TRW5ITVJ?
SW48 M3vKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX4dGxTUUN3ME2yOk45QDJizszN M162SnNCVkeHUh?=
IGR-1 MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnRTWM2OD1{Nj65N|M1KM7:TR?= NIHGRZRUSU6JRWK=
639-V NUPEOohST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHFTWM2OD1{Nz6wNlQ2KM7:TR?= NHXrU4NUSU6JRWK=
LK-2 MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDQWnUzUUN3ME2yO{41OTRzIN88US=> NIfSU5VUSU6JRWK=
NCI-H2347 NYT5[Yw6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TrOGlEPTB;MkeuPVY6QSEQvF2= Mn3oV2FPT0WU
NCI-H2228 Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP4OnlKSzVyPUK4MlA6ODVizszN M4PWUnNCVkeHUh?=
LS-123 NWL2Z485T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jvR2lEPTB;MkiuNVI3OiEQvF2= M4f6XnNCVkeHUh?=
U031 MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVntRlNHUUN3ME2yPE4zPTJizszN M3\TSXNCVkeHUh?=
NCI-H1792 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJ6LkS3NlEh|ryP NGnpPJhUSU6JRWK=
NCI-H2087 MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD1[GFDUUN3ME2yPE44PTV{IN88US=> NIjuO4lUSU6JRWK=
NCI-H2342 NGL6NJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHJR3dzUUN3ME2yPU42OjB6IN88US=> Mk\nV2FPT0WU
SW626 M13WbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJ7Lke1OkDPxE1? NGqwcVJUSU6JRWK=
LB2518-MEL Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XNTmlEPTB;MkmuPFE2KM7:TR?= NWP1cop5W0GQR1XS
RXF393 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\CTWM2OD1|MD6wPVUzKM7:TR?= MUnTRW5ITVJ?
LC4-1 MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXOR2t5UUN3ME2zNE4{ODl{IN88US=> M3i3dXNCVkeHUh?=
NCI-H1694 NUPpSmJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTNyLk[2NlQh|ryP MnLqV2FPT0WU
K5 M{DjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLoeXFKSzVyPUOwMlk4ODJizszN MnvKV2FPT0WU
HDLM-2 Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3CRmVKSzVyPUOwMlk4OjVizszN MX7TRW5ITVJ?
BCPAP NILPZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHRXWZKSzVyPUOxMlg{PzlizszN NXi2[Vk2W0GQR1XS
BC-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlS5TWM2OD1|Mj6xOFA{KM7:TR?= Ml3zV2FPT0WU
LB996-RCC MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXs[29KSzVyPUOyMlI{PThizszN NGLDPG1USU6JRWK=
NCI-H2009 M1vUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTN{LkS5PFEh|ryP NXvqfWFWW0GQR1XS
HTC-C3 NHG5SnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rX[2lEPTB;M{OuO|UyQSEQvF2= NWn2Uo5OW0GQR1XS
LAMA-84 NFy4Z4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml33TWM2OD1|ND60OFA4KM7:TR?= M1[3ZnNCVkeHUh?=
CCRF-CEM NInRbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz1PJNKSzVyPUO0MlU4OTVizszN NWHyenFYW0GQR1XS
AN3-CA MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTN3LkC1Olgh|ryP MWDTRW5ITVJ?
NCI-H1734 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXHN2lKSzVyPUO1MlI2PjFizszN M2TCc3NCVkeHUh?=
Ca-Ski Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3tTWM2OD1|NT60NVAyKM7:TR?= NXO5Z4RHW0GQR1XS
U-266 MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTN3Lk[xNVQh|ryP NXPkSpF5W0GQR1XS
SBC-5 NVjVOnc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjwbnRKSzVyPUO1Mlc4QDFizszN NEL2SY5USU6JRWK=
GT3TKB M1\WXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;NeGlEPTB;M{euNVE2KM7:TR?= NXHiZ3dnW0GQR1XS
MDA-MB-175-VII MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTN5LkKyOFgh|ryP M{\DWHNCVkeHUh?=
PFSK-1 M2HFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX0e|hIUUN3ME2zO{4zPDN3IN88US=> M2TufnNCVkeHUh?=
IMR-5 NUH0PGxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK1TIJKSzVyPUO3MlI1QDdizszN MlXVV2FPT0WU
Daudi M1LRT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTN5LkO1PVch|ryP NUPiSJdRW0GQR1XS
A498 NWjQ[2NpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPWPYxKSzVyPUO3MlczOThizszN M3XNT3NCVkeHUh?=
SCC-4 NF61PIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLKb2xNUUN3ME2zO{44QDR|IN88US=> NXrGZllNW0GQR1XS
COLO-680N MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTN6LkK4PFUh|ryP MnT0V2FPT0WU
SK-MES-1 Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTN6LkOyNVUh|ryP M2\DUHNCVkeHUh?=
SR NHjCOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL0SJdOUUN3ME2zPE42PDl3IN88US=> NHXkTotUSU6JRWK=
LNCaP-Clone-FGC NIDWdoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTN6LkW2N|ch|ryP M{LG[3NCVkeHUh?=
SK-HEP-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTN6Lke4NlIh|ryP MXnTRW5ITVJ?
BPH-1 NHO0VIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P1bmlEPTB;M{iuPFMzQSEQvF2= NF71OHhUSU6JRWK=
NCI-H1755 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfROmhKSzVyPUO5MlU5OTdizszN MmXGV2FPT0WU
LXF-289 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPLNnpKSzVyPUO5MlgxQDRizszN M32zfXNCVkeHUh?=
SW1088 MmXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\WcmJKSzVyPUSwMlIyODdizszN MWDTRW5ITVJ?
MOLT-4 NFnEW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO1TWM2OD12MD6yPVAyKM7:TR?= NFixZVZUSU6JRWK=
AsPC-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTRyLkS1PFMh|ryP NXXFboszW0GQR1XS
HOP-62 Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe0U|VKSzVyPUSwMlY2PjhizszN MV\TRW5ITVJ?
A172 M{Pmc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnVZ3RlUUN3ME20NE45PTFzIN88US=> MnzCV2FPT0WU
SN12C NFfCUItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTRyLkmzPFUh|ryP MmXsV2FPT0WU
MDA-MB-231 M2fwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jKdWlEPTB;NECuPVg6QCEQvF2= MUTTRW5ITVJ?
RPMI-2650 NXPBe|dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXRTWM2OD12MT6xOVk{KM7:TR?= NYiy[VdnW0GQR1XS
KYSE-140 NYW2PHJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\3VmlEPTB;NEGuPFEzOyEQvF2= MXPTRW5ITVJ?
KINGS-1 M3fubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1n0SGlEPTB;NEKuOFY6PyEQvF2= NVfrZ41YW0GQR1XS
HSC-3 NXLkOWhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrofJpKSzVyPUSyMlY3PjFizszN MlrmV2FPT0WU
PC-14 MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LjWGlEPTB;NEOuNVg5OiEQvF2= M17qcnNCVkeHUh?=
COR-L105 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzSeFZKUUN3ME20N{43PTB{IN88US=> Mn3BV2FPT0WU
BE-13 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTR2LkKzO|Eh|ryP MXHTRW5ITVJ?
NCI-H661 NFq3dIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHFSIRKSzVyPUS0MlI6PThizszN NFzjO2tUSU6JRWK=
IST-MEL1 NVPvS4l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfKdJF2UUN3ME20OE4{PTl7IN88US=> MlzLV2FPT0WU
HCC1806 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7nS2lKSzVyPUS0MlU5PzNizszN M2jjRnNCVkeHUh?=
COLO-800 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPMeXN1UUN3ME20OE45PDV|IN88US=> NH76Nm9USU6JRWK=
IST-SL2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVWyWJA1UUN3ME20OU4yOjR5IN88US=> M2\wcHNCVkeHUh?=
8305C NWj3dGR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDJeWJKSzVyPUS1MlMxQSEQvF2= NYS0fYlKW0GQR1XS
UACC-62 NGXlZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHyzTG5KSzVyPUS2MlI5PzVizszN NHKzOoRUSU6JRWK=
COR-L23 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTR5LkG5PUDPxE1? MVTTRW5ITVJ?
EFE-184 NX\5VZpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTwTWM2OD12Nz6zPFgh|ryP M2TUdnNCVkeHUh?=
DMS-114 NYPpZYlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTR5LkSxOFkh|ryP NUnBPIdpW0GQR1XS
KYSE-520 NXHTfHk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnIOY1KSzVyPUS4MlU{OTVizszN M2K2[XNCVkeHUh?=
SNG-M MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn4TWM2OD12OT60N|Qh|ryP Ml3VV2FPT0WU
A2058 M{HjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTR7LkS4PFUh|ryP NWTEcVluW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; 

PubMed: 26052929     


Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells.

p-IGF1R / IGF1R / p-mTOR / mTOR ; 

PubMed: 28440057     


Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot.

cleaved caspase-3 / cleaved PARP; 

PubMed: 28440057     


Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control.

pSrc(Y416) / Src; 

PubMed: 26515601     


A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis.

p-STAT3(Y705) / STAT3 ; 

PubMed: 26041671     


H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days.

pS6 / S6; 

PubMed: 21257723     


Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.

26052929 28440057 26515601 26041671 21257723
Immunofluorescence
FoxO1; 

PubMed: 27535223     


After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min.  A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.

27535223
Growth inhibition assay
Cell viability; 

PubMed: 26136493     


InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.

26136493
In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
+ Expand

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
+ Expand
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Formulation: 25 mM tartaric acid
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG 400+0.5% Tween 80+5% Propylene glycol
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development Inc.|Astellas Pharma Inc April 16 2014 Phase 2
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development Inc.|Astellas Pharma Inc April 16 2014 Phase 2
NCT02546544 Completed Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT02546544 Completed Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • Answer:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products4

Tags: buy Linsitinib (OSI-906) | Linsitinib (OSI-906) supplier | purchase Linsitinib (OSI-906) | Linsitinib (OSI-906) cost | Linsitinib (OSI-906) manufacturer | order Linsitinib (OSI-906) | Linsitinib (OSI-906) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID